Swing For A Cure 2013 - Register Here

Click Here to Register!!

Progress in SMA Drug Treatments - Exciting News!

Pfizer Licenses Families of Spinal Muscular Atrophy Quinazoline Drug Program from Repligen.

January 3, 2013.

Repligen Corporation announced today that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. to advance Repligen’s spinal muscular atrophy (SMA) program, originally in-licensed from Families of SMA (FSMA).

Families of SMA funded and directed the preclinical . . . → Read More: Progress in SMA Drug Treatments – Exciting News!

3rd Annual Dance Away SMA - Details Ticket Orders

Please Join us on Saturday September 29th, 2012 to Dance Away SMA Where: Schnecksville Fire Company Pavilion                   4550 Old Packhouse Road ~ Schnecksville, PA 18078   When: Saturday, September 29th  ~ 5:30 – 10:00      Cost: $25/ticket (includes a hot dinner, alcohol, and entertainment by          . . . → Read More: 3rd Annual Dance Away SMA – Details & Ticket Orders

Swing for a Cure for SMA 2012 - Details and Registration Available Now

Swing for a Cure 2012

Swing for a Cure was a great success!! With beautiful weather and a great turnout we were able to raise over $2,100 for Families of SMA!! We are looking forward to next years event! Join us for a great time and to raise funds to find a cure for SMA.  . . . → Read More: Swing for a Cure for SMA 2012 – Final Update!!

Team Lyla receives donation from Pencor Services, Inc. parent of Blue Ridge Communications

We would like to thank Pencor Services, Inc., the parent company of Blue Ridge Communications for a generous donation of $428 to the Lyla Mertz Foundation in our continued mission to find a cure for Spinal Muscular Atrophy.  On December 1st  Blue Ridge Communications held a company wide “Dress Down Day” with employees donating $1 . . . → Read More: Team Lyla receives donation from Pencor Services, Inc. parent of Blue Ridge Communications

Isis Pharmaceuticals Initiates Phase 1 Clinical Study in Patients with Spinal Muscular Atrophy

This article was published by FSMA on December 19th.

Isis Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 study of ISIS-SMNRx in patients with spinal muscular atrophy (SMA).  Isis is developing ISIS-SMNRx as a potential treatment for all types of SMA.

The Phase 1 study of ISIS-SMNRx is a single-dose, dose-escalation study . . . → Read More: Isis Pharmaceuticals Initiates Phase 1 Clinical Study in Patients with Spinal Muscular Atrophy

Flea Market to raise funds for SMA!!

One mans junk is another mans treasure!! Have some free time on Saturday, November 5th? Come visit the flea market at the Northampton County Senior Center in Centre Square Easton.  The event runs from 8 – 2 PM.

Have stuff to sell? Rent a table the day of the event or just stop by to . . . → Read More: Flea Market to raise funds for SMA

Repligen Corporation Provides Update on the Phase I Trial for the SMA Drug 3039

Attached is an update regarding a drug trial being funded by Families of SMA.  These are the types of programs that our fundraising helps to support.

 

Repligen Corporation provided a short update in their quarterly report released today on the Phase I Trial in adult volunteers on the Spinal Muscular Atrophy Drug RG3039.  This is . . . → Read More: Repligen Corporation Provides Update on the Phase I Trial for the SMA Drug 3039

Welcome to the new Team Lyla Website!!

Thanks for visiting!!  It has been a long time coming but we finally got our new website up and running!!  The new site is going to allow us to more easily keep everyone informed of all of our events and keep everyone updated on medical news and breakthroughs on SMA Research.

New Updates:

More Social . . . → Read More: Welcome to the new Team Lyla Website!!

Families of Spinal Muscular Atrophy Awards 7 New Basic Research Grants

Families of SMA Awards 7 New Basic Research Grants for $745,000 to Develop New Approaches for SMA Therapies. 

October 18, 2011.

In the Fall 2011 issue of “Compass” Families of Spinal Muscular Atrophy announces seven new basic research grant awards. These new awards encompass $745,000 for the basic research portion of the $3 Million in . . . → Read More: Families of SMA Awards 7 New Basic Research Grants